Floatz logo

PREDNISONE TABLETS

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

University of WashingtonSmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 cohort.

Asset / SponsorPhaseRating
Blinatumomab
OHSU Knight Cancer Institute
Phase 2B
METHOTREXATE
OHSU Knight Cancer Institute
Phase 2B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 2B
(+)-VINCRISTINE
University of Washington
Phase 2B
Cyclophosphamide
University of Washington
Phase 2B

View all 29 →

Same molecule, other indications

PREDNISONE TABLETS is also rated in:

Recurrent Adult T-cell Leukemia/LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
diffuse large B-cell lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →